Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders

References

• Abbot NJ. Physiology of the blood–brain barrier and its consequences for drug transport to the brain. Int Congr Series 2005;1277:3–18.
   Google Scholar
• Gray SJ, Kalburgi SN, McCown TJ, Samulski J. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 2013;20:450–459.
   PubMed Web of Science ®Google Scholar
• Hamani C, Pilitsis J, Rughani AI, et al. Deep brain stimulation for obsessive-compulsive disorder: systematic review and evidence-based guideline sponsored by the American Society for Stereotactic and Functional Neurosurgery and the Congress of Neurological Surgeons (CNS) and endorsed by the CNS and American Association of Neurological Surgeons. Neurosurgery 2014;75:327–333.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRX 2005;2:3–14.
   PubMedGoogle Scholar
• Rabin C, Liang Y, Ehrlichman RS, et al. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res 2008;98:67–78.
   Web of Science ®Google Scholar
• Bulloch AGM, Pattern SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol 2010;45:47–56.
   PubMed Web of Science ®Google Scholar
• Breen R, Thornhill JT. Noncompliance with medication for psychiatric disorders: reasons and remedies. CNS Drugs 1998;9:457–471.
   Web of Science ®Google Scholar
• Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: a review. PharmacoEconomics 2008;26:149–162.
   PubMed Web of Science ®Google Scholar
• Ferrara M, Langiano E, Di Brango T, et al. Prevalence of stress, anxiety and depression in with Alzheimer caregivers. Health Qual Life Outcomes 2008;6:93–106.
   PubMed Web of Science ®Google Scholar
• Gelperina S. Nanoparticulate drug delivery systems for the non-invasive chemotherapy of brain tumors. NSTI Nanotechnology Conference and Trade Show, Boston, USA, 2006.
   Google Scholar
• Koo YL, Reddy GR, Bhojani M, et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006;58:1556–1577.
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. The blood-brain barrier and brain drug delivery. J Nanosci Nanotechnol 2006;6:2712–2735.
   PubMed Web of Science ®Google Scholar
• Krauze MT, Forsayeth J, Park JW, Bankiewicz KS. Real-time imaging and quantification of brain delivery of liposomes. Pharm Res 2006;23:2493–2504.
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliver 2006;3:219–232.
   PubMedGoogle Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1–20.
   PubMed Web of Science ®Google Scholar
• Wang PP, Frazier J, Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002;54:987–1013.
   PubMed Web of Science ®Google Scholar
• Guo L, Ren J, Jiang X. Perspectives on brain-targeting drug delivery systems. Curr Pharm Biotechnol 2012;13:2310–2318.
   PubMed Web of Science ®Google Scholar
• Scherrmann JM. Drug delivery to brain via the blood-brain barrier. Vascul Pharmacol 2002;38:349–354.
   PubMed Web of Science ®Google Scholar
• Upadhyay RK. Drug delivery systems, CNS protection and the blood brain barrier. BioMed Res Int 2014;2014:1–37.
   Web of Science ®Google Scholar
• Guo-Yu P, Xiao-Dong L, Guo-Quing L. Intracarotid infusion of hypertonic mannitol changes permeability of blood-brain barrier to methotrexate in rats. Acta Pharmacol Sin 2000;21:613–616.
   PubMed Web of Science ®Google Scholar
• Bryan J. Crossing the blood-brain barrier: drug delivery to the brain is still elusive. Pharm J 2004;273:475–476.
   Google Scholar
• Raghavan R, Brady ML, Rodríguez-Ponce MI, et al. Convection-enhanced delivery of therapeutics for brain disease and its optimization. Neurosurg Focus 2006;20:E12.
   PubMedGoogle Scholar
• Ferber D. Bridging the blood-brain barrier: new methods improve the odds of getting drugs to the brain cells that need them. PLoS Biol 2007;5:e169.
   Google Scholar
• Jain KK. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) 2012;7:225–233.
   Web of Science ®Google Scholar
• Illum l. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1–18.
   PubMed Web of Science ®Google Scholar
• Quay SC. Successful delivery of apomorphine to the brain following intranasal administration demonstrated in clinical study. PR Newswire, 18 July 2001.
   Google Scholar
• Frey WH. Interview, Reuters Health, 16 Feb 2001.
   Google Scholar
• Sahni JK, Doggui S, Ali J, et al. Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. J Control Release 2011;152:208–231.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev 2014;71:2–14.
   PubMed Web of Science ®Google Scholar
• Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104:29–45.
   PubMed Web of Science ®Google Scholar
• Mayberg M, Langer R, Zervas N, Moskowitz M. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 1981;2:228–230.
   Web of Science ®Google Scholar
• During MJ, Freese A, Sabel BA, et al. Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann Neurol 1989;25:351–356.
   PubMed Web of Science ®Google Scholar
• Freese A, Sabel BA, Saltzman WM, et al. Controlled release of dopamine from a polymeric brain implant: in vitro characterization. Exp Neurol 1989;103:234–238.
   PubMed Web of Science ®Google Scholar
• Aoi M, Date I, Tomita S, Ohmoto T. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res 2000;36:319–325.
   PubMed Web of Science ®Google Scholar
• Nakao N, Yokote H, Nakai K, Itakura T. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson’s disease after implantation of embryonal carcinomaderived neurons genetically engineered to produce glial cell line-derived neurotrophic factor. J Neurosurg 2000;92:659–670.
   PubMed Web of Science ®Google Scholar
• Tornqvist N, Bjorklund L, Almqvist P, et al. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson’s disease. Exp Neurol 2000;164:130–138.
   PubMed Web of Science ®Google Scholar
• Jollivet C, Aubert-Pouessel A, Clavreul A, et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson’s disease. Biomaterials 2004;25:933–942.
   PubMed Web of Science ®Google Scholar
• Pillay S, Pillay V, Choonara YE, et al. Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm 2009;382:277–290.
   PubMed Web of Science ®Google Scholar
• Howard MA, Gross A, Grady MS, et al. Intracerebral drug delivery in rats with lesion-induced memory deficits. J Neurosurg 1989;71:105–112.
   PubMed Web of Science ®Google Scholar
• Powell EM, Sobarzo MR, Saltzman WM. Controlled release of nerve growth factor from a polymeric implant. Brain Res 1990;515:309–311.
   PubMed Web of Science ®Google Scholar
• Albani D, Gloria A, Giordano C, et al. Hydrogel-based nanocomposites and mesenchymal stem cells: a promising synergistic strategy for neurodegenerative disorders therapy. Scient World J 2013;2013:270260.
   Web of Science ®Google Scholar
• Wahlberg LU, Lind G, Almqvist PM, et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg 2012;117:340–347.
   PubMed Web of Science ®Google Scholar
• Menei P, Pean JM, Nerrie, et al. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp Neurol 2000;161:259–272.
   PubMed Web of Science ®Google Scholar
• Ludvig N, Medveczky G, French JA, et al. Evolution and prospects for intracranial pharmacotherapy for refractory epilepsies: the subdural hybrid neuroprosthesis. Epilepsy Res Treat 2010;2010:1–10.
   Google Scholar
• Kokaia M, Aebischer P, Elmér E, et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp Brain Res 1994;100:385–394.
   PubMed Web of Science ®Google Scholar
• Kubek MJ, Liang D, Byrd KE, Domb AJ. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res 1998;809:189–197.
   PubMed Web of Science ®Google Scholar
• Tamargo RJ, Rossell LA, Kossoff EH, et al. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res 2002;48:145–155.
   PubMed Web of Science ®Google Scholar
• Lopez T, Ortiz E, Quintana P, Gonzalez RD. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain. Colloids Surf A Physicochem Eng Asp 2007;300:3–10.
   Web of Science ®Google Scholar
• Lopez T, Quintana P, Ascencio J, Gonzalez RD. The determination of dielectric constants of mixtures used in the treatment of epilepsy and the encapsulation of phenytoin in a titania matrix. Colloid Surf A Physicochem Eng Asp 2007;300:99–105.
   Web of Science ®Google Scholar
• Salam MT, Hamie AH, Nguyen DK, Sawan M. A smart biological signal responsive focal drug delivery system for treatment of refractory epilepsy. Adv Sci Technol 2013;85:39–46.
   Google Scholar
• Rickus J. A hybrid cell-silicon neural prosthesis for the treatment of epilepsy. Available from: http://www.ninds.nih.gov/research/epilepsyweb/curingepilepsy/Rickus.pdf [last accessed 21 March 2010].
   Google Scholar
• Gulati K, Aw MS, Losic D. Nanoengineered drug-releasing Ti wires as an alternative for local delivery of chemotherapeutics in the brain. Int J Nanomedicine 2012;7:2069–2076.
   PubMed Web of Science ®Google Scholar
• Guerin C, Olivi A, Weingart JD, et al. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 2004;22:27–37.
   PubMed Web of Science ®Google Scholar
• Jain JP, Modi S, Domb AJ, Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005;103:541–563.
   PubMed Web of Science ®Google Scholar
• Wahlberg LU, Almqvist PM, Glantz MJ, Boethius J. Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model. Acta Neurochir (Wien) 1996;138:1323–1330.
   PubMed Web of Science ®Google Scholar
• Li Y, Owusu A, Lehnert S. Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:519–527.
   PubMed Web of Science ®Google Scholar
• Chen W, He J, Olson JJ, Lu DR. Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization. Drug Deliv 1997;4:301–311.
   PubMed Web of Science ®Google Scholar
• Menei P, Venier MC, Gamelin E, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer 1999;86:325–330.
   PubMed Web of Science ®Google Scholar
• Menei P, Jadaud E, Faisant N, et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer 2004;100:405–410.
   PubMed Web of Science ®Google Scholar
• Roullin VG, Mege M, Lemaire L, et al. Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization. Pharm Res 2004;21:1558–1563.
   PubMed Web of Science ®Google Scholar
• Pèan JM, Menei P, Morel O, et al. Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. Biomaterials 2000;21:2097–2101.
   PubMed Web of Science ®Google Scholar
• Ranganath SH, Wang C. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials 2008;29:2996–3003.
   PubMed Web of Science ®Google Scholar
• Lee JS, An TK, Chae GS, et al. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma. Eur J Pharm Biopharm 2005;59:169–175.
   PubMed Web of Science ®Google Scholar
• Scott AW. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials 2011;32:2532–2539.
   PubMed Web of Science ®Google Scholar
• Upadhyay UM, Tyler B, Patta Y, et al. Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. PNAS 2014;111:16071–16076.
   PubMed Web of Science ®Google Scholar
• Reinhard CS, Radomsky ML, Saltzman WM, et al. Polymeric controlled release of dexamethasone in normal rat brain. J Control Release 1991;16:33l–340.
   Google Scholar
• Siegel SJ, Winey KI, Gur RE, et al. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology 2002;26:817–823.
   PubMed Web of Science ®Google Scholar
• Iyer SS, Barr WH, Dance ME, et al. A ‘biorelevant’ system to investigate in vitro drug released from a naltrexone implant. Int J Pharm 2007;340:104–118.
   PubMed Web of Science ®Google Scholar
• Montoya ID, Vocci F. Novel medications to treat addictive disorders. Curr Psychiatry Rep 2008;10:392–398.
   PubMedGoogle Scholar
• Reece AS. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine. J Subst Abuse Treat 2009;37:256–265.
   PubMed Web of Science ®Google Scholar
• White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 2009;103:37–43.
   PubMed Web of Science ®Google Scholar
• The British Pain Society. Intrathecal drug delivery for the management of pain and spasticity in adults; recommendations for best clinical practice; 2008.
   Google Scholar
• Jeon Y, Kwak K, Kim S, et al. Intrathecal implants of microencapsulated xenogenic chromaffin cells provide a long-term source of analgesic substances. Transplant Proc 2006;38:3061–3065.
   PubMed Web of Science ®Google Scholar
• Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technol Today 2000;3:318–326.
   PubMedGoogle Scholar
• Mavuso S, Marimuthu T, Choonara YE, et al. A review of polymeric colloidal nanogels in transdermal drug delivery. Curr Pharm Des 2015;21:2801–2813.
   PubMed Web of Science ®Google Scholar
• Lan Y, Wang J, Li H, et al. Effect of menthone and related compounds on skin permeation of drugs with different lipophilicity and molecular organization of stratum corneum lipids. Pharm Dev Technol 2016;21:389–398.
   PubMed Web of Science ®Google Scholar
• Balfour DJK, Fagerström KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 1996;72:51–81.
   PubMed Web of Science ®Google Scholar
• Rezvani AH, Levin ED. Nicotine mechanisms in Alzheimer’s disease: cognitive effects of nicotine. Biol Psychiatry 2001;49:258–267.
   PubMed Web of Science ®Google Scholar
• Quik M. Smoking, nicotine and Parkinson’s disease. Trends Neurosci 2004;27:561–568.
   PubMed Web of Science ®Google Scholar
• Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson’s disease. Prog Neurobiol 2007;81:29–44.
   PubMed Web of Science ®Google Scholar
• Arnold LE, Lindsay RL, Lopez FA, et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007;120:1100–1106.
   PubMed Web of Science ®Google Scholar
• Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2002;25:150–168.
   Web of Science ®Google Scholar
• Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiat 2003;64:208–214.
   PubMed Web of Science ®Google Scholar
• Indermun S, Luttge R, Choonara YE, et al. Current advances in the fabrication of microneedles for transdermal delivery. J Control Release 2014;185:130–138.
   PubMed Web of Science ®Google Scholar